Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 6, 2014, Pages 1186-1191

  Jiang, Yingjie ^a   Nie, Yuqiang ^a   Li, Yuyuan ^a   Zhang, Long ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cannabinoid receptor 1; Fatty acid amide hydrolase; Genetic polymorphisms; Irritable bowel syndrome

Indexed keywords

CANNABINOID 1 RECEPTOR; FATTY ACID AMIDASE; AMIDASE; CNR1 PROTEIN, HUMAN; FATTY-ACID AMIDE HYDROLASE;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; TRINUCLEOTIDE REPEAT;

ADULT; AMIDOHYDROLASES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; TRINUCLEOTIDE REPEATS;

EID: 84900551351     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12513     Document Type: Article

References (43)

1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-1390.
2. Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J. Gastroenterol. Hepatol. 2009; 24: 1601-1607.
3. Bassotti G, Chistolini F, Marinozzi G, Morelli A. Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome. Digestion 2003; 68: 178-183.
4. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am. J. Gastroenterol. 2001; 96: 1499-1506.
5. Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002; 50: 471-474.
6. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 14-19.
7. Simren M, Agerforz P, Bjornsson ES, Abrahamsson H. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol. Motil. 2007; 19: 20-29.
8. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992; 102: 102-108.
9. Dinh TP, Carpenter D, Leslie FM etal. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl Acad. Sci. U.S.A. 2002; 99: 10819-10824.
10. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl Acad. Sci. U.S.A. 1997; 94: 2238-2242.
11. Pinto L, Izzo AA, Cascio MG etal. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002; 123: 227-234.
12. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 293: G137-145.
13. Hinds NM, Ullrich K, Smid SD. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br. J. Pharmacol. 2006; 148: 191-199.
14. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006; 58: 389-462.
15. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol. Motil. 2006; 18: 949-956.
16. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005; 5: 400-411.
17. Hoehe MR, Caenazzo L, Martinez MM etal. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol. 1991; 3: 880-885.
18. Dawson E. Identification of a polymorphic triplet repeat make marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiatr. Genet. 1995; 5: S50.
19. Schroth GP, Chou PJ, Ho PS. Mapping Z-DNA in the human genome. Computer-aided mapping reveals a nonrandom distribution of potential Z-DNA-forming sequences in human genes. J. Biol. Chem. 1992; 267: 11846-11855.
20. Comings DE. Polygenic inheritance and micro/minisatellites. Mol. Psychiatry 1998; 3: 21-31.
21. Park JM, Choi MG, Cho YK etal. Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: a hypothesis-generating study. J. Clin. Gastroenterol. 2011; 45: 45-49.
22. Cravatt BF, Demarest K, Patricelli MP etal. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. U.S.A. 2001; 98: 9371-9376.
23. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384: 83-87.
24. Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. 2003; 7: 469-475.
25. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum. Mol. Genet. 2004; 13: 2113-2119.
26. Camilleri M, Carlson P, McKinzie S etal. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 294: G13-19.
27. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl Acad. Sci. U.S.A. 2002; 99: 8394-8399.
28. Camilleri M, Katzka DA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G1075-1084.
29. Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res. 2000; 302: 73-80.
30. n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J. 2006; 6: 126-130.
31. Barrero FJ, Ampuero I, Morales B etal. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 2005; 5: 135-141.
32. Comings DE, Muhleman D, Gade R etal. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol. Psychiatry 1997; 2: 161-168.
33. n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur. Arch. Psychiatry Clin. Neurosci. 2006; 256: 437-441.
34. Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr. Genet. 2000; 10: 149-151.
35. Saito YA, Petersen GM, Locke GR 3rd, Talley NJ. The genetics of irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2005; 3: 1057-1065.
36. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-1040.
37. Li Y, Nie Y, Xie J etal. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig. Dis. Sci. 2007; 52: 2942-2949.
38. Wong BS, Camilleri M, Busciglio I etal. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 2011; 141: 1638-47 e1-7.
39. Covault J, Gelernter J, Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol. Psychiatry 2001; 6: 501-502.
40. Krebs MO, Leroy S, Duaux E etal. Vulnerability to cannabis, schizophrenia, the (ATT)n polymorphism of the cannabinoid receptor type 1 (CNR1) gene (abstract). Schizophr. Res. 2002; 53: 72.
41. n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol. Psychiatry 2000; 5: 128-130.
42. Ujike H, Takaki M, Nakata K etal. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 2002; 7: 515-518.
43. Zhang PW, Ishiguro H, Ohtsuki T etal. Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol. Psychiatry 2004; 9: 916-931.